DOI: https://dx.doi.org/10.18565/therapy.2022.8.20-31
Т.Ю. Демидова, М.Я. Измайлова
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, г. Москва
1. Soyoye D.O., Abiodun O.O., Ikem R.T. et al. Diabetes and peripheral artery disease: A review. World J Diabetes. 2021; 12(6): 827–38. https://dx.doi.org/10.4239/wjd. v12.i6.827. 2. Ren H., Zhao L., Zou Y. et al. Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. Ren Fail. 2021; 43(1): 477–87. https://dx.doi.org/10.1080/0886022X.2021.1893186. 3. Holscher M.E., Bode C., Bugger H. Diabetic cardiomyopathy: Does the type of diabetes matter? Int J Mol Sci. 2016; 17(12): 2136. https://dx.doi.org/10.3390/ijms17122136. 4. ADVANCE Collaborative Group; Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560–72. https://dx.doi.org/10.1056/NEJMoa0802987. 5. Duckworth W., Abraira C., Moritz T. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2): 129–39. https://dx.doi.org/10.1056/NEJMoa0808431. 6. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein H.C., Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545–59. https://dx.doi.org/10.1056/NEJMoa0802743. 7. Thiruvoipati T., Kielhorn C.E., Armstrong E.J. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes 2015; 6(7): 961–69. https://dx.doi.org/10.4239/wjd.v6.i7.961. 8. Weitz J.I., Byrne J., Clagett G.P. et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation. 1996; 94(11): 3026–49. https://dx.doi.org/10.1161/01.cir.94.11.3026. Erratum in: Circulation 2000; 102(9): 1074. 9. Navaneethan S.D., Zoungas S., Caramori M.L. et al. Diabetes management in chronic kidney disease: Synopsis of the 2020 KDIGO clinical practice guideline. Ann Intern Med. 2021; 174(3): 385–94. https://dx.doi.org/10.7326/M20-5938. 10. Nevola R., Alfano M., Pafundi P.C. et al. Cardiorenal impact of SGLT-2 inhibitors: A conceptual revolution in the management of type 2 diabetes, heart failure and chronic kidney disease. Rev. Cardiovasc. Med. 2022; 23(3): 106. https://dx.doi.org/10.31083/j.rcm2303106. 11. Pfeffer M.A., Shah A.M., Borlaug B.A. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019; 124(11): 1598–617. https://dx.doi.org/10.1161/CIRCRESAHA.119.313572. 12. Gede P., Lund-Andersen H., Parving H.-H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6): 580–91. https://dx.doi.org/10.1056/NEJMoa0706245. 13. Gede P., Oellgaard J., Carstensen B. et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the steno-2 randomised trial. Diabetologia. 2016; 59(11): 2298–307.https://dx.doi.org/10.1007/s00125-016-4065-6. 14. American Diabetes Association. Diabetes care in the hospital: Standards of medical care in diabetes-2020. Diabetes Care. 2020; 43(Suppl 1): S1–202. https://dx.doi.org/10.2337/dc20-S015. 15. Rawshani Ai., Rawshani Ar., Franzen S. et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018; 379(7): 633–44. https://dx.doi.org/10.1056/NEJMoa1800256. 16. Akhtar S., Asghar N. Risk factors of cardiovascular disease in district Swat. J Pak Med Assoc. 2015; 65(9): 1001–4. 17. Kornelius E., Chiou J.-Y., Yang Y.-S. et al. The diabetes shared care program and risks of cardiovascular events in type 2 diabetes. Am J Med. 2015; 128(9): 977–85. https://dx.doi.org/10.1016/j.amjmed.2015.03.025. 18. Mahmood S.S., Levy D., Vasan R.S., Wang T.J. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. Lancet. 2014; 383(9921): 999–1008. https://dx.doi.org/10.1016/S0140-6736(13)61752-3. 19. Ballotari P., Venturelli F., Greci M. et al. Sex differences in the effect of type 2 diabetes on major cardiovascular diseases: Results from a population-based study in Italy. Int J Endocrinol. 2017; 2017: 6039356. https://dx.doi.org/10.1155/2017/6039356. 20. Cheung B.M., Li C. Diabetes and hypertension: Is there a common metabolic pathway? Curr Atheroscler Rep. 2012; 14(2): 160–66. https://dx.doi.org/10.1007/s11883-012-0227-2. 21. Ninomiya T., Kubo M., Doi Y. et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: The Hisayama study. Stroke. 2007; 38(7): 2063–69. https://dx.doi.org/10.1161/STROKEAHA.106.479642. 22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837–53. 23. Ference B.A., Ginsberg H.N., Graham I. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459–72. https://dx.doi.org/10.1093/eurheartj/ehx144. 24. Доборджгинидзе Л.М., Грацианский Н.А. Особенности диабетической дислипидемии и пути ее коррекции: эффект статинов. Проблемы эндокринологии. 2001; 47(5): 35–40. 25. Kaze A.D., Santhanam P., Musani S.K. et al. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: Findings from the look AHEAD Study. J Am Heart Assoc. 2021; 10(7): e016947. https://dx.doi.org/10.1161/JAHA.120.016947. Erratum in: J Am Heart Assoc. 2021; 10(14): e020749. 26. Ndumele C.E., Matsushita K., Lazo M. et al. Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. 2016; 5(8): e003921. https://dx.doi.org/10.1161/JAHA.116.003921. 27. Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5): 968–77. https://dx.doi.org/10.1161/01.cir.67.5.968. 28. Wilson P.W., Bozeman S.R., Burton T.M. et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation. 2008; 118(2): 124–30. https://dx.doi.org/10.1161/CIRCULATIONAHA.108.772962. 29. Morkedal B., Vatten L.J., Romundstad P.R. et al. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trondelag Health Study), Norway. J Am Coll Cardiol. 2014; 63(11): 1071–78.https://dx.doi.org/10.1016/j.jacc.2013.11.035. 30. Calle E.E., Thun M.J., Petrelli J.M. et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999; 341(15): 1097–105. https://dx.doi.org/10.1056/NEJM199910073411501. 31. Manson J.E., Willett W.C., Stampfer M.J. et al. Body weight and mortality among women. N Engl J Med. 1995; 333(11): 677–85.https://dx.doi.org/10.1056/NEJM199509143331101.
Татьяна Юльевна Демидова, д.м.н., профессор, зав. кафедрой эндокринологии лечебного факультета ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России. Адрес: 117997, г. Москва, ул. Островитянова, д. 1. E-mail: t.y.demidova@gmail.com.
ORCID: https://orcid.org/0000-0001-6385-540X. eLIBRARY.RU SPIN: 9600-9796. ScopusAuthorID: 7003771623
Марьям Ярагиевна Измайлова, ассистент кафедры эндокринологии лечебного факультета ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России. Адрес: 117997, г. Москва, ул. Островитянова, д. 1. E-mail: maremizm@gmail.com.
ORCID: https://orcid.org/0000-0002-1385-0245